iSpecimen reports Q1 revenue of $3.0M (+17% YoY); net loss flat at $2.4M

iSpecimen Inc.

2023-Q1 EPS reported -$0.25 revenue$2,950,197

Revenue $3.0M vs $2.5M in Q1 2022, a 17% increase; specimen count up 75% but ASP down 30%.
Net loss $2.4M ($0.27 per share), unchanged YoY; cash, equivalents and securities totaled $11M at Mar 31 vs $15.3M at Dec 31.
Unique customer organizations reached 534 (+22%); registered marketplace users ~6,900 (+24%).
CEO Tracy Curley cited progress on adjacent revenue opportunities and technology investment.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

iSpecimen Inc. reported first quarter of 2023 results: revenue Revenue was approximately $3.0 million, net income Net loss was approximately $2.4 million, or $(0.27) per share, EPS $(0.27) per share.

Period: first quarter of 2023
Revenue: Revenue was approximately $3.0 million
Net income: Net loss was approximately $2.4 million, or $(0.27) per share
EPS: $(0.27) per share
Result: reported results

Exact text from the filing

reported its financial and operating results for the three-month period ended March 31, 2023. “I am pleased to report that iSpecimen delivered strong revenue of approximately $3.0 million, a 17% increase year-over-year for the first quarter of 2023, which met our internal expectations and reflects the seasonality of our business,” said Tracy Curley, CEO and CFO.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

iSpecimen Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-055829

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.